Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
15.89
+0.68 (4.47%)
At close: Aug 13, 2025, 4:00 PM
15.61
-0.28 (-1.76%)
Pre-market: Aug 14, 2025, 8:33 AM EDT
Immunovant Employees
Immunovant had 362 employees as of March 31, 2025. The number of employees increased by 155 or 74.88% compared to the previous year.
Employees
362
Change (1Y)
155
Growth (1Y)
74.88%
Revenue / Employee
n/a
Profits / Employee
-$1,235,644
Market Cap
2.77B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMVT News
- 3 days ago - Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 - GlobeNewsWire
- 2 months ago - Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 - GlobeNewsWire
- 5 months ago - Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward - Seeking Alpha
- 5 months ago - Immunovant's muscle disorder treatment meets main goal in late-stage trial - Reuters
- 5 months ago - Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies - GlobeNewsWire
- 5 months ago - Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - GlobeNewsWire
- 6 months ago - Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 - GlobeNewsWire
- 7 months ago - Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - PRNewsWire